Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR-104

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Benito, Juliana ^a   Shi, Yuexi ^a   Szymanska, Barbara ^b   Carol, Hernan ^b   Boehm, Ingrid ^b   Lu, Hongbo ^a   Konoplev, Sergej ^a   Fang, Wendy ^a   Zweidler McKay, Patrick A ^a   Campana, Dario ^c   Borthakur, Gautam ^a   Bueso Ramos, Carlos ^a   Shpall, Elizabeth ^a   Thomas, Deborah A ^a   Jordan, Craig T ^d   Kantarjian, Hagop ^a   Wilson, William R ^e   Lock, Richard ^e   Andreeff, Michael ^a   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; NITROBENZENE DERIVATIVE; PR 104; PR 104A; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD45 ANTIGEN; CHLORMETHINE DERIVATIVE; PR-104;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROTECTION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; HYPOXIA; IMMUNE DEFICIENCY; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CELL DEATH; CELL HYPOXIA; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; PATHOLOGY; REMISSION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

MURINAE; MUS;

ANIMALS; ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; MICE; MODELS, BIOLOGICAL; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051628334     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023108     Document Type: Article

References (54)

1. Chitteti BR, Cheng YH, Poteat B, Rodriguez-Rodriguez S, Goebel WS, et al. (2010) Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function. Blood 115: 3239-3248 blood-2009-09-246173 [pii];10.1182/blood-2009-09-246173 [doi].
2. Iwasaki H, Suda T, (2009) Cancer stem cells and their niche. Cancer Sci 100: 1166-1172 CAS1177 [pii];10.1111/j.1349-7006.2009.01177.x [doi].
3. Lane SW, Scadden DT, Gilliland DG, (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114: 1150-1157 blood-2009-01-202606 [pii];10.1182/blood-2009-01-202606 [doi].
4. Li Z, Li L, (2006) Understanding hematopoietic stem-cell microenvironments. Trends Biochem Sci 31: 589-595 S0968-0004(06)00207-6 [pii];10.1016/j.tibs.2006.08.001 [doi].
5. Perry JM, Li L, (2007) Disrupting the stem cell niche: good seeds in bad soil. Cell 129: 1045-1047.
6. Xie Y, Yin T, Wiegraebe W, He XC, Miller D, et al. (2009) Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457: 97-101 nature07639 [pii];10.1038/nature07639 [doi].
7. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, et al. (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118: 149-161.
8. Arai F, Suda T, (2007) Regulation of hematopoietic stem cells in the osteoblastic niche. Adv Exp Med Biol 602: 61-67.
9. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL, (2005) Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599-1611.
10. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD, (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proceedings of the National Academy of Sciences of the United States of America 104: 5431-5436.
11. Winkler IG, Barbier V, Wadley R, Zannettino ACW, Williams S, et al. (2010) Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 116: 375-385 DOI 10.1182/blood-2009-07-233437.
12. Thompson JE, Conlon JP, Yang X, Sanchez PV, Carroll M, (2007) Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol 35: 21-31 S0301-472X(06)00550-9 [pii];10.1016/j.exphem.2006.08.017 [doi].
13. Jensen PO, Mortensen BT, Hodgkiss RJ, Iversen PO, Christensen IJ, et al. (2000) Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 33: 381-395.
14. Mortensen BT, Jensen PO, Helledie N, Iversen PO, Ralfkiaer E, et al. (1998) Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 102: 458-464.
15. Wilson WR, Hay MP, (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410 nrc3064 [pii];10.1038/nrc3064 [doi].
16. Semenza GL, (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634 onc2009441 [pii];10.1038/onc.2009.441 [doi].
17. Weidemann A, Johnson RS, (2008) Biology of HIF-1alpha. Cell Death Differ 15: 621-627 cdd200812 [pii];10.1038/cdd.2008.12 [doi].
18. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, et al. (2010) Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 7: 391-402 S1934-5909(10)00344-9 [pii];10.1016/j.stem.2010.06.020 [doi].
19. Simsek T, Kocabas F, Zheng J, Deberardinis RJ, Mahmoud AI, et al. (2010) The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7: 380-390 S1934-5909(10)00347-4 [pii];10.1016/j.stem.2010.07.011 [doi].
20. Wellmann S, Guschmann M, Griethe W, Eckert C, von Stackelberg A, et al. (2004) Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 18: 926-933.
21. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732 10.1038/nrc1187 [doi];nrc1187 [pii].
22. Cairns R, Papandreou I, Denko N, (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4: 61-70 4/2/61 [pii];10.1158/1541-7786.MCR-06-0002 [doi].
23. Brown JM, William WR, (2004) Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 4: 437-447.
24. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, et al. (2008) A RNA antagonist of hypoxia-inducible factor-1 alpha, EZN-2968, inhibits tumor cell growth. Molecular Cancer Therapeutics 7: 3598-3608.
25. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421.
26. Loboda A, Jozkowicz A, Dulak J, (2010) HIF-1 and HIF-2 transcription factors-similar but not identical. Mol Cells 29: 435-442 10.1007/s10059-010-0067-2 [doi].
27. Stratford IJ, Williams KJ, Cowen RL, Jaffar M, (2003) Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin Radiat Oncol 13: 42-52 10.1053/srao.2003.50008 [doi];S1053-4296(03)50007-8 [pii].
28. Patterson AV, Ferry DM, Edmunds SJ, Gu YC, Singleton RS, et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clinical Cancer Research 13: 3922-3932.
29. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, et al. (2009) DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res 69: 3884-3891.
30. Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, et al. (2007) Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110: 2578-2585.
31. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, et al. (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65: 791-801 10.1007/s00280-009-1188-1 [doi].
32. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70: 1573-1584 0008-5472.CAN-09-3237 [pii];10.1158/0008-5472.CAN-09-3237 [doi].
33. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, et al. (2009) The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res 662: 67-74 S0027-5107(08)00321-7 [pii];10.1016/j.mrfmmm.2008.12.010 [doi].
34. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, et al. (2004) Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103: 3905-3914 10.1182/blood-2003-08-2911 [doi];2003-08-2911 [pii].
35. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, et al. (2007) The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49: 928-940 10.1002/pbc.21078 [doi].
36. Schaefer C, Krause M, Fuhrhop I, Schroeder M, Algenstaedt P, et al. (2008) Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia 22: 59-65 2404947 [pii];10.1038/sj.leu.2404947 [doi].
37. MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, et al. (2007) Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 27: 3282-3289 MCB.01927-06 [pii];10.1128/MCB.01927-06 [doi].
38. Kim WY, Kaelin WG, (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004 22/24/4991 [pii];10.1200/JCO.2004.05.061 [doi].
39. Kizaka-Kondoh S, Konse-Nagasawa H, (2009) Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci 100: 1366-1373 CAS1195 [pii];10.1111/j.1349-7006.2009.01195.x [doi].
40. Hu J, Handisides DR, Van VE, De RH, Menu E, et al. (2010) Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116: 1524-1527 blood-2010-02-269126 [pii];10.1182/blood-2010-02-269126 [doi].
41. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, et al. (2010) Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24: 1967-1970 leu2010193 [pii];10.1038/leu.2010.193 [doi].
42. semenza gl, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732 10.1038/nrc1187 [doi];nrc1187 [pii].
43. Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, et al. (2009) CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113: 1504-1512.
44. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
45. Franovic A, Holterman CE, Payette J, Lee S, (2009) Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 106: 21306-21311 0906432106 [pii];10.1073/pnas.0906432106 [doi].
46. Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund J, et al. (2009) HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci U S A 106: 16805-16810 0904606106 [pii];10.1073/pnas.0904606106 [doi].
47. Taylor CT, Cummins EP, (2009) The role of NF-kappaB in hypoxia-induced gene expression. Ann N Y Acad Sci 1177: 178-184 NYAS5024 [pii];10.1111/j.1749-6632.2009.05024.x [doi].
48. Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud O, (2009) Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. Crit Rev Oncog 15: 1-41 1aaaaf156ec9f641,0ec1b8dd079de327 [pii].
49. Tracey L, Streck CJ, Du Z, Williams RF, Pfeffer LM, et al. (2010) NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia. Leukemia 24: 806-812 leu20102 [pii];10.1038/leu.2010.2 [doi].
50. Sung B, Ahn KS, Aggarwal BB, (2010) Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer Res 70: 3259-3268 0008-5472.CAN-09-4230 [pii];10.1158/0008-5472.CAN-09-4230 [doi].
51. Jin Y, Lu Z, Ding K, Li J, Du X, et al. (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 70: 2516-2527 0008-5472.CAN-09-3950 [pii];10.1158/0008-5472.CAN-09-3950 [doi].
52. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, et al. (2007) Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. International Journal of Radiation Oncology Biology Physics 69: 560-571.
53. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, et al. (2010) Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 10.1002/pbc.22921 [doi].
54. Zeng ZH, Shi YX, Samudio IJ, Wang RY, Ling XY, et al. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113: 6215-6224.